Insulet Corporation
Insulet Corporation (PODD) manufactures and sells tubeless insulin pump systems for diabetes management, with a dominant political signal being $3.8M in annual doctor payments (2024) and a single congressional trader making two purchases in August 2025.
BusinessWhat PODD does
Insulet Corporation designs, manufactures, and sells the Omnipod System, a tubeless insulin pump for people with insulin-dependent diabetes. Its revenue is primarily derived from the sale of its disposable Pods and associated Dash and Omnipod 5 handheld devices. The company operates in the medical device sector, specifically focused on diabetes care technology.
12 months past · 3 months futurePODD activity timeline
Executive Branch ConflictsPODD held by Trump-administration officials
Lifetime Government AwardsPODD federal contracts
PODD doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding PODD
Politicians Trading PODDMembers of Congress with recent PODD positions
Congressional TradesWho in Congress is trading PODD
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting PODDLive legislation impacting this stock
Political ProfileWhere PODD sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) due to healthcare sector and $3.8M in annual doctor payments (2024), but zero lobbying spend, zero donations, and no federal contracts. EVIDENTIARY: Single congressional trader (Rep. Khanna) made two purchases in Aug 2025; former President Trump holds two positions (common stock and dividends) per executive_branch_exposure.by_ticker[0].holdings. No corporate insider buys in 180 days. Net: Mixed signals with moderate evidentiary interest offset by lack of structural political engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payments under Sunshine Act, given $3.8M in annual doctor payments (2024).CMS (Centers for Medicare & Medicaid Services)"get_political_influence.doctor_payments[0].total_payment_usd: 3821252.6 for 2024."
-
Potential legislative changes to Medicare/Medicaid reimbursement for durable medical equipment (DME) and diabetes supplies.Congress, CMS"Recent bill_impacts array shows 8 healthcare bills with estimated revenue impacts ranging from $3.19M to $6.06M."
Regulatory opportunities
-
Potential expansion of coverage for insulin pump systems under federal healthcare programs.CMS"Recent bill_impacts array indicates legislative activity in healthcare sector affecting company revenue."
-
Reduced regulatory barriers for next-generation automated insulin delivery systems.FDA"Inherent for medical device companies in diabetes sector, though no specific RPC field cites FDA activity."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for PODD — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades PODD
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord